The US Food and Drug Administration (FDA) has accepted the filing of Vanda’s Supplemental New Drug Application for HETLIOZ (tasimelteon) for the treatment of jet lag disorder.

The FDA determined the action target date under Prescription Drug User Fee Act (PDUFA-VI), to be August 16, 2019.

HETLIOZ is currently approved for the treatment of non-24 hour sleep-wake disorder.